Company Profile
PROCEPT BioRobotics Stock Price, News & Analysis
- Ticker:
- PRCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
20.03 USD (+3.57%)
Close
Last updated: August 6, 2026
1.52B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PRCT closed up 3.57% at $20.03. No new same-company headline was identified in the current news window.
Company overview
Urology Robotics
PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies.
Aquablation Therapy
Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive prostate tissue. The procedure is planned from imaging and is intended to reduce dependence on surgeon technique compared with manually executed resection.
HYDROS Platform
The HYDROS Robotic System is the company’s current AI-enabled platform for Aquablation. Its FirstAssist AI software supports personalized image-guided planning, while recurring handpiece sales create a procedure-linked revenue stream alongside capital-system placements.
Future catalysts
PROCEPT BioRobotics's catalysts are Aquablation adoption, prostate-procedure growth, and continued system rollout. The company matters most when the procedure base keeps widening.
Recent news
- 01
PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
Source: PROCEPT BioRobotics
- 02
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
Source: PROCEPT BioRobotics
- 03
- 04
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
Source: PROCEPT BioRobotics
- 05
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
Source: PROCEPT BioRobotics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PROCEPT BioRobotics (PRCT)?
PROCEPT BioRobotics (PRCT) most recently closed at 20.03 USD, a +3.57% move versus the previous session.
What is the market cap of PROCEPT BioRobotics (PRCT)?
PROCEPT BioRobotics currently has a market capitalization of 1.52B USD on BioPharmSignal.
What does PROCEPT BioRobotics do?
Urology Robotics PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies. Aquablation Therapy Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive...
On which exchange is PRCT stock listed?
PROCEPT BioRobotics (PRCT) is associated with NASDAQ, United States, Biopharma.
What is Urology?
Urology Robotics PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia.
Which conditions is PROCEPT BioRobotics targeting with Urology?
Urology Robotics PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies. Aquablation Therapy Aquablation uses a robotically controlled, heat-free waterjet to remove obstructive...
How does PROCEPT BioRobotics describe recent progress with Urology?
PROCEPT BioRobotics's catalysts are Aquablation adoption, prostate-procedure growth, and continued system rollout. The company matters most when the procedure base keeps widening.
What is Robotics?
Urology Robotics PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia.